In 2024, Baiyunshan Pharmaceutical Holdings completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
However, Baiyunshan Pharmaceutical Holdings has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021-2019 |
|---|---|---|---|---|
Total Scope 1 | 34,042.94a | 171,468.81a | 48,290.8a | |
Total Scope 2 | ||||
Unspecified Calculation Method | 137,330.89a | 123,327.38a | 116,732.99a | |
Total Scope 3 | 430,312a | 17,042.21a | N/A | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 3.313a | 16.1375a | 4.7501a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of Baiyunshan Pharmaceutical Holdings amounted to 171,373.83 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Baiyunshan Pharmaceutical Holdings decreased by 41.87%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
In 2024, the total Scope 1 emissions of Baiyunshan Pharmaceutical Holdings were 34,042.94 metric tons of CO₂ equivalent (tCO₂e).a
Since 2021, Baiyunshan Pharmaceutical Holdings's Scope 1 emissions have decreased by 4.14%, reflecting a declining long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2023), Baiyunshan Pharmaceutical Holdings's Scope 1 emissions decreased by 80.15%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
In 2024, Baiyunshan Pharmaceutical Holdings reported Scope 2 greenhouse gas (GHG) emissions of 137,330.89 tCO₂e without specifying the calculation method.a
Since 2021, Baiyunshan Pharmaceutical Holdings's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have increased by 54.83%, reflecting a rising long-term trend in Scope 2 emissions over time.ab
Compared to the previous year (2023), Baiyunshan Pharmaceutical Holdings's Scope 2 emissions (Unspecified Calculation Method) rose by 11.35% in 2024, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya
In 2024, Baiyunshan Pharmaceutical Holdings reported its Scope 2 emissions using an unspecified methodology.a
In 2024, Baiyunshan Pharmaceutical Holdings reported 430,312 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2024 disclosure of Baiyunshan Pharmaceutical Holdings includes a breakdown across 0 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2024, Baiyunshan Pharmaceutical Holdings reported total Scope 3 emissions of 430,312 metric tons of CO₂ equivalent (tCO₂e).a
Compared to the previous year (2023), Baiyunshan Pharmaceutical Holdings's Scope 3 emissions increased by 2,424.98%, suggesting that the company faced challenges in reducing emissions across its value chain.a
In 2024, Baiyunshan Pharmaceutical Holdings reported Scope 1 greenhouse gas (GHG) emissions of 34,042.94 tCO₂e and total revenues of USD 10,276 millions. This translates into an emissions intensity of 3.31 tCO₂e per millions USD.a
In 2024, Baiyunshan Pharmaceutical Holdings reported a Scope 1 emissions intensity of 3.31 tCO₂e per millions USD. Compared to the peer group median of 0.73, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2024, Baiyunshan Pharmaceutical Holdings ranked 21 out of 22 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Baiyunshan Pharmaceutical Holdings among the least efficient performers, with one of the highest emissions intensities in its sector.a
In 2024, Baiyunshan Pharmaceutical Holdings reported a total carbon footprint of 601,685.83 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 92.95% increase compared to 2023, suggesting a rise in emissions across its operations or value chain.a
The largest contributor to Baiyunshan Pharmaceutical Holdings's total carbon footprint was Scope 3 emissions, accounting for 71.52% of the company's total carbon footprint, followed by Scope 2 emissions at 22.82%.a